Bispecific antibodies contain two antigen-binding components within a single molecule enabling the simultaneous binding of two targets and can be designed to neutralise cytokine activity, block signalling pathways or to recruit the effector cells of the immune system. A distinct advantage of bispecific antibodies over conventional antibody therapeutics is their ability to target the T-Cell Receptor-CD3 complex (TCR-CD3) directing the activity of T-cells towards a desired tumour target. T-cells are the most potent of the immune killer cells and upon activation induce a cascade of cytotoxic events and represent attractive immunotherapy targets.
The biological activity of T-cell engaging bispecific antibodies can be determined using TDCC (T-Cell Dependent Cellular Cytotoxicity) assays supported with CD3-antigen binding assays. The TDCC assay follows a similar format to that of the ADCC assay, in which the bispecific forms a bridge between target cells expressing and T-cells present within the effector preparation. As with ADCC assays, TDCC assays are complex methods with many formats requiring the use of primary cell types and expertise to run successfully.
With proprietary cell lines expressing common bispecific antigen targets, cell line development capabilities and access to a wide variety of primary T-cells, we can develop industry-leading TDCC assays to support early screening activities through to development of lot release potency methods.
Our services include a diverse range of assay formats
Cell-based Binding Assays (Flow Cytometry & ELISA)
Cell Death & Apoptosis
Cell Proliferation & Viability
ADCC, CDC & ADCP
Ligand Binding assays
Reporter Gene Assays
Want to find out more or discuss a project? Please click here to contact us